Sangamo Therapeutics, Inc. (SGMO)

0,5220 -0,0218 (-4,01%) Alla chiusura: 04:00PM EDT

Sangamo Therapeutics, Inc.

501 Canal Blvd
Richmond, CA 94804
United States
510-970-6000
https://www.sangamo.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 405

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.	CEO, President & Director	722,67k	N/D	1963
Dr. Nathalie Dubois-Stringfellow Ph.D.	Senior VP & Chief Development Officer	459,9k	N/D	1962
Ms. Amy Pooler Ph.D.	Head of Research	N/D	N/D	N/D
Mr. Gregory Davis Ph.D.	Head of Technology	N/D	N/D	N/D
Ms. Aron Feingold	Head of Corporate Communications & Investor Relations Officer	N/D	N/D	N/D
Mr. Scott B. Willoughby	Senior VP, General Counsel & Corporate Secretary	N/D	N/D	1975
Phillip Ramsey	Head of Technical Operations	N/D	N/D	N/D
Ms. Stephanie J. Seiler CLP	Head of Business Development & Alliance Management	N/D	N/D	N/D
Mr. David Ojala	Scientist II - Discovery & Translational Research	N/D	N/D	N/D
Louise Wilkie	Vice President of Investor Relations & Corporate Communications	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Governance aziendale

L'ISS Governance QualityScore di Sangamo Therapeutics, Inc. al 1 maggio 2024 è 3. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 1; diritti degli azionisti: 2; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.